Search
Related
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS.
Cancer. 2012 May 17. doi: 10.1002/cncr.27575. [Epub ahead of print
22605616
[PubMed - as supplied by publisher] nohighlight
Related citations
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG, Riely GJ.
Cancer. 2012 May 17. doi: 10.1002/cncr.27637. [Epub ahead of print
22605530
[PubMed - as supplied by publisher] nohighlight
Related citations
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Mayo C, Bertran-Alamillo J, Molina-Vila MÁ, Giménez-Capitán A, Costa C, Rosell R.
Pharmacogenomics. 2012 May;13(7):789-802
22594511
[PubMed - in process] nohighlight
Related citations
Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis.
Nakamura Y, Takahashi T, Tsuya A, Naito T, Kenmotsu H, Ono A, Shukuya T, Murakami H, Harada H, Watanabe R, Endo M, Mitsuya K, Nakajima T, Yamamoto N.
Anticancer Res. 2012 May;32(5):1811-6
22593466
[PubMed - in process] nohighlight
Related citations
Utility of Insulin-like Growth Factor Receptor-1 Expression in Gefitinib-Treated Patients with Non-small Cell Lung Cancer.
Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi P.
Anticancer Res. 2012 May;32(5):1705-10
22593449
[PubMed - in process] nohighlight
Related citations
Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819.
Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR.
Clin Cancer Res. 2012 May 16. [Epub ahead of print
22592956
[PubMed - as supplied by publisher] nohighlight
Related citations
Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesise.
Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.
J Thorac Oncol. 2012 May 15. [Epub ahead of print
22592212
[PubMed - as supplied by publisher] nohighlight
Related citations
Detection of EGFR Somatic Mutations in Non-Small Cell Lung Cancer (NSCLC) Using a Novel Mutant-Enriched Liquidchip (MEL) Technology.
Zhang L, Yang H, Zhao Y, Liu W, Wu S, He J, Luo X, Zhu Z, Xu J, Zhou Q, Ren-Heidenreich L.
Curr Drug Metab. 2012 May 16. [Epub ahead of print
22591345
[PubMed - as supplied by publisher] nohighlight
Related citations
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.
Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, Perou CM, Hayes DN.
PLoS One. 2012;7(5):e36530. Epub 2012 May 10
22590557
[PubMed - in process] Free PMC Article nohighlight
Related citations
Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors.
Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, Deangelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.
Cancer Discov. 2012 May;2(5):458-471. Epub 2012 Mar 31
22588883
[PubMed - as supplied by publisher] nohighlight
Related citations
Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers.
Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, Shokat KM, Nicolaides T, Weiss WA.
Cancer Discov. 2012 May;2(5):450-7. Epub 2012 Mar 31
22588882
[PubMed - in process] nohighlight
Related citations
Occupy EGFR.
Park JH, Lemmon MA.
Cancer Discov. 2012 May;2(5):398-400
22588876
[PubMed - in process] nohighlight
Related citations
Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation.
de Lima Araújo LH, da Silveira JS, Baldotto CS, Zukin M, Ferreira CG.
J Thorac Oncol. 2012 Jun;7(6):1059-60. No abstract available.
22588158
[PubMed - in process] nohighlight
Related citations
Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping.
Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M, Arcila ME.
J Thorac Oncol. 2012 Jun;7(6):1049-52
22588155
[PubMed - in process] nohighlight
Related citations
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers.
Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC.
Cancer Discov. 2011 Dec;1(7):608-25. Epub 2011 Oct 17
22586683
[PubMed - in process] nohighlight
Related citations
The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells.
Yang PW, Hung MC, Hsieh CY, Tung EC, Wang YH, Tsai JC, Lee JM.
Lasers Med Sci. 2012 May 15. [Epub ahead of print
22585382
[PubMed - as supplied by publisher] nohighlight
Related citations
Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.
Ruan CJ, Liu DY, Jiang J, Hu P.
Eur J Clin Pharmacol. 2012 May 15. [Epub ahead of print
22585284
[PubMed - as supplied by publisher] nohighlight
Related citations
Ocular Adverse Events of Systemic Inhibitors of the Epidermal Growth Factor Receptor: Report of 5 Cases.
Saint-Jean A, Sainz de la Maza M, Morral M, Torras J, Quintana R, Molina JJ, Molina-Prat N.
Ophthalmology. 2012 May 12. [Epub ahead of print
22584020
[PubMed - as supplied by publisher] nohighlight
Related citations
Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial.
Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T.
Oncologist. 2012 May 11. [Epub ahead of print
22581822
[PubMed - as supplied by publisher] nohighlight
Related citations
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature.
Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.
Lung Cancer. 2012 May 11. [Epub ahead of print
22579408
[PubMed - as supplied by publisher] nohighlight
Related citations